Clinical Trial Detail

NCT ID NCT03345134
Title Pembrolizumab in Combination With BCG After Ablation in Patients With UUTTCC Without Nephroureterectomy
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Shaheen Alanee
Indications

renal pelvis transitional cell carcinoma

ureter transitional cell carcinoma

Therapies

BCG solution + Pembrolizumab

Age Groups: senior adult

No variant requirements are available.